Safety Findings Appear Encouraging for REGN5458 in Relapsed/Refractory Myeloma
Deepu Madduri, MD, discusses the safety findings from a first-in-human phase 1 study of REGN5458, a BCMA x CD3 bispecific monoclonal antibody, as treatment of patients with relapsed/refractory multiple myeloma.
Deepu Madduri, MD, assistant professor of medicine, hematology and medical oncology and assistant professor of urology at Mount Sinai, discusses the safety findings from a first-in-human phase 1 study (NCT03761108) of REGN5458, a BCMA x CD3 bispecific monoclonal antibody, as treatment of patients with relapsed/refractory multiple myeloma.
Cytokine release syndrome (CRS) and cytopenias are a big concern with bispecifics, says Madduri. Most grade 3 or higher toxicities observed in this trial were hematological, as expected, but the infection rate of grade 3 or higher was only 18%. The median time to onset of CRS was about 18 hours, but this event only occurred in 19 of the 49 patients. All cases of CRS were grade 1/2, and no grade 3 or higher CRS were observed.
According to Madduri, there was no relationship observed between the dose and CRS, nor CRS and response.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Supportive Care Helps Manage AEs With Teclistamab in R/R Multiple Myeloma
December 13th 2024During a Case-Based Roundtable® event, Hana Safah, MD, discussed updated data and adverse event management related to teclistamab in patients with multiple myeloma in the second article of a 2-part series.
Read More
